Author + information
- Received December 13, 2012
- Revision received July 23, 2013
- Accepted August 9, 2013
- Published online December 1, 2013.
- Takashi Fujita, MD∗,
- Noboru Fujino, MD∗,
- Ryuichiro Anan, MD†,
- Chuwa Tei, MD†,
- Toru Kubo, MD‡,
- Yoshinori Doi, MD‡,
- Shintaro Kinugawa, MD§,
- Hiroyuki Tsutsui, MD§,
- Shigeki Kobayashi, MD‖,
- Masafumi Yano, MD‖,
- Masanori Asakura, MD¶,
- Masafumi Kitakaze, MD¶,
- Issei Komuro, MD#,
- Tetsuo Konno, MD∗,
- Kenshi Hayashi, MD∗,
- Masa-aki Kawashiri, MD∗,
- Hidekazu Ino, MD∗ and
- Masakazu Yamagishi, MD∗∗ ()
- ∗Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan
- †Department of Cardiovascular, Respiratory and Metabolic Medicine, Kagoshima University, Kagoshima, Japan
- ‡Department of Medicine and Geriatrics, Kochi Medical School, Nankoku, Japan
- §Department of Cardiovascular Medicine, Hokkaido University School of Medicine, Sapporo, Japan
- ‖Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Ube, Japan
- ¶Department of Clinical Research and Development, National Cerebral and Cardiovascular Center, Suita, Japan
- #Department of Cardiovascular Medicine, University of Tokyo Graduate School of Medicine, Tokyo, Japan
- ↵∗Reprint requests and correspondence:
Dr. Masakazu Yamagishi, Division of Cardiovascular Medicine, Kanazawa University Graduate School of Medicine, 13-1, Takara-machi, Kanazawa, Ishikawa 920-8641, Japan.
Objectives This study investigated the occurrence of cardiovascular events in patients with hypertensive heart disease (HHD) or hypertrophic cardiomyopathy (HCM) with or without sarcomere gene mutations.
Background Although HHD and HCM are associated with left ventricular hypertrophy (LVH), few data exist regarding the difference in prognosis between them.
Methods We enrolled 256 patients with LVH (>13 mm) screened for sarcomere gene mutations. We divided them into 3 groups: the first had HHD without sarcomere gene mutations (group H), the second had sarcomere gene mutations (group G), and the third had neither sarcomere gene mutations nor HHD (group NG). We compared the occurrence of sudden cardiac death, ventricular tachycardia/fibrillation, admission for heart failure, and atrial fibrillation for 1 year.
Results Group G (n = 78, 36 men; mean age, 53.4 years) experienced more total cardiovascular events than group H (n = 45, 32 men; mean age, 67.4 years) (p = 0.042) after adjustments for age and sex, although there was no significant difference in total cardiovascular events between groups H and NG (n = 98, 66 men; mean age, 62.0 years). With Kaplan-Meier analysis, group G exhibited a significantly higher incidence of admission for heart failure (p = 0.017) and atrial fibrillation (p = 0.045) than group H in those 50 years of age and older. Additionally, there was a significant difference in total cardiovascular events between groups G and NG (p = 0.021).
Conclusions These results demonstrate that HCM with sarcomere gene mutations can be associated with increased cardiovascular events compared with HHD or HCM without sarcomere gene mutations.
This work was supported by a research grant for cardiovascular diseases (20C-4) from the Ministry of Health, Welfare, and Labor of Japan. The authors have reported that they have no relationships relevant to the contents of this paper to disclose. Part of this work was presented at the Annual Scientific Sessions, American Heart Association, 2012, Los Angeles, California.
- Received December 13, 2012.
- Revision received July 23, 2013.
- Accepted August 9, 2013.
- American College of Cardiology Foundation